Compare Novo Nordisk A/S (NVO) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Open Text Corporation — how do they compare? Novo Nordisk A/S trades at $44.73 (market cap $200.69B), while Open Text Corporation trades at $22.6 (market cap $5.64B). The key difference: Novo Nordisk A/S is far larger — about 35.6× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.8%). Which is the better fit depends on your goals.
| NVO | OTEX | |
|---|---|---|
Market Cap | $200.69B | $5.64B |
Sector | Health | Technology |
52-Week High | $63.98 | $39.69 |
52-Week Low | $35.29 | $20.01 |
Enterprise Value | $215.49B | $10.66B |
Dividend Yield | 3.98% | 4.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Open Text Corp (OTEX) trades at $23.36, down 2.46% on the day, with a bearish technical signal but attractive valuation multiples (P/E 9.05, P/S 1.11). Recent earnings beats (Q4 2025, Q1 2026, Q2 2026) and a 4.7% dividend yield highlight fundamental strength. The company announced a $105 million investment in European AI and cloud expansion (PRNewsWire, 2026-06-12), signaling growth initiatives amid mixed institutional positioning.
Outlook: Undervalued with strong cash flow and earnings momentum, but near-term technical pressure and high debt ($6.34B) pose risks. Analyst consensus target of $29.33 suggests 25% upside, supported by cloud revenue growth. Key risks include execution on AI investments and competitive software market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
